New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
09:03 EDTROSGRosetta Genomics receives patent for ovarian cancer treatment
Rosetta Genomics announces receipt of a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application No. 13/977,797, entitled "Compositions and Methods for Treatment of Ovarian Cancer." The patent relates to inhibition of miR-210 for the treatment of ovarian cancer. Treatment for advanced ovarian carcinoma is typically based on the combination of surgery and chemotherapy. The objective of surgical intervention in patients suffering from advanced disease is to perform cyto-reduction to minimal residual disease in the abdominal cavity. Surgery is followed by adjuvant platinum based chemotherapy. Although 80%-90% of patients initially respond to first line treatment, most will either progress during therapy or recur after complete remission. Ovarian cancer causes more deaths than any other gynecologic cancer.
News For ROSG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 12, 2015
08:17 EDTROSGRosetta Genomics sees 2H14 revenue to be 40% above 1H14
Rosetta Genomics announces the posting of a Letter to Shareholders from President and CEO Kenneth Berlin to investors, in which he stated in part: "Throughout 2014 we made significant progress advancing our three key areas for growth: current product sales, new product development and third-party collaborations...We expect revenue for the second half of 2014 to be approximately 40% higher compared with the first half of 2014, and to be more than three times the revenue we recorded in the second half of 2013. While we are still in the early stages of our full commercialization efforts and these increases are off a modest base, the growth and trends demonstrate that our strategy and marketing programs are bearing fruit as we continue to progress our microRNA-based solutions for oncology...We remain vigilant in continuing to build and strengthen our intellectual property, and are pleased to have added three U.S. patents to our growing portfolio during 2014. As a result we now have 39 issued patents, including 35 in the U.S. In addition we have 49 patent applications pending, of which 28 are in the U.S. These issued patents and applications protect the specific microRNAs used in our products and cover composition of matter, diagnostic applications, therapeutic applications and discovery process applications for microRNAs in humans...We are very pleased with the progress we have made and expect 2015 to be an exciting year of growth and accomplishments as we advance our strategic plan in pursuit of our mission to be the pioneering force in microRNA-based personalized medicine to the benefit of patients worldwide." One revenue estimate $1.14M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use